All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2022-11-04T12:18:14.000Z

Zanubrutinib receives EC approval for the treatment of R/R marginal zone lymphoma

Nov 4, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in marginal zone lymphoma.

Bookmark this article

On November 2, 2022, it was announced that the European Commission had granted approval to zanubrutinib, a Bruton’s tyrosine kinase inhibitor, for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior line of anti-CD20-based therapy.1

The approval follows a positive opinion granted by the European Medicine Agency’s Committee for Medicinal Products for Human Use in September of this year and is based on key results of the phase II MAGNOLIA trial (NCT03846427). In the trial, zanubrutinib demonstrated a high overall response rate and acceptable safety in marginal zone lymphoma, consistent with its established profile.

  1. Business Wire. BeiGene receives European Commission approval for BRUKINSA® (zanubrutinib) for the treatment of adults with marginal zone lymphoma. https://www.businesswire.com/news/home/20221102005244/en/BeiGene-Receives-European-Commission-Approval-for-BRUKINSA%C2%AE-zanubrutinib-for-the-Treatment-of-Adults-with-Marginal-Zone-Lymphoma. Published Nov 2, 2022. Accessed Nov 3, 2022.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
60 votes - 48 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox